definiens: means ( a ) Sellers ’ biologic anti - VEGF therapy bui lt with Sellers ’ proprietary antibody biopolymer conjugate platform, commonly known as KS I-301, which, as of the date hereof is being develo ped by Sellers in announced Clinical Trials for ( i ) wet age - related macular degeneration ( AMD ), ( ii ) diabe tic macular edema ( DME ), ( iii ) retinal vein occlusion ( includin g branch retinal vein occlusion ( BRVO ) and central retinal vein occlusion ( CRVO ) ) and ( iv ) diabetic retinopath y ( DR ), and ( b ) any product or therapy not describe d in ( a ), the rights to which are owned or controlled by Sell ers or any of its Subsidiaries that ( i ) is built wi th Sellers ’ proprietary antibody biopolymer conjugate platform, and ( ii ) contains an anti - VEGF as its sole molecul ar or chemical biology